Abstract
Intracranial microdialysis was utilized to assess the effects of the novel neurotensin antagonist SR 48692 on extracellular γ-amino-butyric acid (GABA) and glycine in the striatum. Subcutaneous injection of SR 48692 (0.2 mg/kg) significantly decreased extracellular striatal GABA levels, with peak decreases occurring 2–3 h post-injection. Injection of SR 48692 had no significant effect on glycine levels. These data suggest that endogenous neurotensin may modulate striatal GABA levels.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
